Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology

PULSE BIOSCIENCES, INC.

GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.
Placed nsPFA Percutaneous Electrode System at 7 US pilot sites; pivotal trial for thyroid nodules expected mid-2025.
Over 50 patients treated with nano-PFA 360 catheter in European feasibility study; two additional study sites engaged.
Appointed Dr. David Kenigsberg as CMO of Electrophysiology; added Dr. Andrea Natale as medical advisor.
Cash burn $8.5M in Q3; warrants could raise up to $66M at $11/share, exercisable immediately.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.